News Related to PrimeC

Related coverage linked through entity extraction aliases.

JAMA Neurology Publishes PrimeC Phase 2b ALS Data as NeuroSense Advances Toward Phase 3

Apr 06, 2026

JAMA Neurology published Phase 2b PARADIGM results for PrimeC in ALS, showing slower functional decline, fewer ALS-related complications and longer survival. NeuroSense is preparing a Phase 3 trial and received Brazilian patent protection through October 2042.

Two Experimental ALS Therapies Report Positive Safety Data from Early-Stage Trials

Mar 16, 2026

PrimeC, an oral combination therapy, showed safety and signals of clinical benefit in a phase 2b trial, while PLL001, a gut-targeting therapy, demonstrated positive safety and tolerability in a phase I/II study for amyotrophic lateral sclerosis.